Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice

Journal of Autoimmunity

Volumn 20, Issue 1, 2003, Pages 15-25

  Braun, Déborah ^a,b   Geraldes, Pedro ^a   Demengeot, Jocelyne ^a  

^a INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

Autoimmunity; Immunoglobulin; Inflammation; Lymphocytes; Mouse

Indexed keywords

GAMMA INTERFERON RECEPTOR; POLYINOSINIC POLYCYTIDYLIC ACID;

ANIMAL MODEL; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNITY; BIOACCUMULATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EVALUATION; KIDNEY DISEASE; LYMPHOPROLIFERATIVE DISEASE; MOUSE; MUTATION; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; RECEPTOR GENE; REDUCTION;

EID: 0037320208     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-8411(02)00109-9     Document Type: Article

References (35)

1. Blanco P., Palucka A.K., Gill M., Pascual V., Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 294:2001;1540-1543.
2. Marrack P., Kappler J., Mitchell T. Type I interferons keep activated T cells alive. J Exp Med. 189:1999;521-530.
3. Tough D.F., Borrow P., Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science. 272:1996;1947-1950.
4. Demengeot J., Vasconcellos R., Modigliani Y., Grandien A., Coutinho A. B lymphocyte sensitivity to IgM receptor ligationis independent of maturation stage and locally determined by macrophage-derived beta-interferon. Int Immunol. 9:1997;1677-1685.
5. Braun D., Caramalho I., Demengeot J. Interferon-alpha/beta enhances BCR-dependent B cell responses. Int Immunol. 14:2002;411-419.
6. Wang J., Lin Q., Langston H., Cooper M.D. Resident bone-marrow macrophages produce type 1 interferons that can selectively inhibits interleukine-7-driven growth of B lineage. Immunity. 3:1995;475-484.
7. Su D.M., Wang J., Lin Q., Cooper M.D., Watanabe T. Interferons alpha/beta inhibit IL-7-induced proliferation of CD4- CD8- CD3- CD44+ CD25+ thymocytes, but do not inhibit that of CD4- CD8- CD3- CD44- CD25- thymocytes. Immunology. 90:1997;543-549.
8. Vasconcellos R., Braun D., Coutinho A., Demengeot J. Type I interferon sets the stringency of B cell repertoire selection in the bone marrow. Int Immunol. 11:1999;279-288.
9. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., Tough D.F. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 14:2001;461-470.
10. Bach J.F. Protective role of infections and vaccinations on autoimmune diseases. J Autoimmun. 16:2001;347-353.
11. Belardelli F., Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today. 17:1996;369-372.
12. Bengtsson A.A., Sturfelt G., Truedsson L., Blomberg J., Alm G., Vallin H., et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 9:2000;664-671.
13. Ytterberg S.R., Schnitzer T.J. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 25:1982;401-406.
14. Ronnblom L., Alm G.V. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med. 194:2001;F59-F63.
15. Ronnblom L., Alm G.V. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol. 22:2001;427-431.
16. Cohen P.L., Eisenberg R.A. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol. 9:1991;243-269.
17. Wakeland E.K., Liu K., Graham R.R., Behrens T.W. Delineating the genetic basis of systemic lupus erythematosus. Immunity. 15:2001;397-408.
18. Muller U., Steinhoff U., Reis L.F.L., Hemmi S., Pavlovic J., Zinkernagel R.M., et al. Functional role of type I and type II interferon antiviral defense. Science. 264:1994;1918-1924.
19. Sedgwick J.D., Holt P.G. A solid phase immunoenzymatictechnique for the enumeration of specific antibody secreting cells. J Immunol Methods. 57:1983;301-304.
20. Grandien A., Fucs R., Nobrega A., Andersson J., Coutinho A. Negative selection of multireactive B cell clones in normal adult mice. Eur J Immunol. 24:1994;1345-1352.
21. Field A.K., Tytell A.A., Lampson G.P., Hilleman M.R. Inducers of interferon and host resistance II. Multistranded synthetic polynucleotide complexes . Proc Natl Acad Sci USA. 58:1967;1004-1010.
22. Botto M., Dell'Agnola C., Bygrave A.E., Thompson E.M., Cook H.T., Petry F., et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet. 19:1998;56-59.
23. Gorelik L., Flavell R.A. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 12:2000;171-181.
24. Rozzo S.J., Allard J.D., Choubey D., Vyse T.J., Izui S., Peltz G., et al. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity. 15:2001;435-443.
25. Maldonado M.A., Kakkanaiah V., MacDonald G.C., Chen F., Reap E.A., Balish E., et al. The role of environmental antigens inthe spontaneous development of autoimmunity in MRL-lpr mice. J Immunol. 162:1999;6322-6330.
26. Paroli M., Schiaffella E., Di Rosa F., Barnaba V. Persisting viruses and autoimmunity. J Neuroimmunol. 107:2000;201-204.
27. Gresser J., Morel-Maroger L., Verroust P., Riviere Y., Guillon J.C. Anti-interferon globulin inhibits the development of glomerulonephritis in mice infected at birth with lymphocytic choriomeningitis virus. Proc Natl Acad Sci USA. 75:1978;3413-3416.
28. Gresser I., Maury C., Tovey M., Morel-Maroger L., Pontillon F. Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature. 263:1976;420-422.
29. Kaveri S.V., Dietrich G., Hurez V., Kazatchkine M.D. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol. 86:1991;192-198.
30. Sundblad A., Marcos M.A., Malanchere E., Castro A., Haury M., Huetz F., et al. Observations on the mode of action of normal immunoglobulin at high doses. Immunol Rev. 139:1994;125-158.
31. Conde C., Weller S., Gilfillan S., Marcellin L., Martin T., Pasquali J.L. Terminal deoxynucleotidyl transferase deficiency reduces the incidence of autoimmune nephritis in (New Zealand Black × New Zealand White)F1 mice. J Immunol. 161:1998;7023-7030.
32. Nemazee D., Guiet C., Buerki K., Marshak-Rothstein A. B lymphocytes from the autoimmune-prone mouse strain MLR/lpr manifest an intrinsic defect in tetraparental MRL/lpr in equilibrium DBA/2 chimeras. J Immunol. 147:1991;2536-2539.
33. Sobel E.S., Katagiri T., Katagiri K., Morris S.C., Cohen P.L., Eisenberg R.A. An intrinsic B cell defect is required for the production of autoantibodies in the lpr model of murine systemic autoimmunity. J Exp Med. 173:1991;1441-1449.
34. Santoro T.J., Portanova J.P., Kotzin B.L. The contribution of L3T4+ T cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice. J Exp Med. 167:1988;1713-1718.
35. Jevnikar A.M., Grusby M.J., Glimcher L.H. Prevention of nephritis in major histocompatibility complex class II-deficient MRL-lpr mice. J Exp Med. 179:1994;1137-1143.